The Global Infectious Disease Treatment Market is growing mainly due to the rising prevalence of infectious diseases. According to a recent study report published by the Market Research Future, The global infectious disease treatment market is booming and expected to gain prominence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).
Global Infectious Disease Treatment Market – Competitive Analysis:
The global infectious disease treatment market is currently dominated by few players. GlaxoSmithKline is one of them by holding a strong share in the market. GSK plc. is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. As one of the few healthcare companies researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria, the company has developed some of the leading global medicines in these fields. On Nov 22, 2017, Johnson & Johnson, and GlaxoSmithKline received FDA approval for an innovative combination of two drugs i.e. Tivicay/rilpivirine and Edurant/dolutegravir, to treat HIV infection.
Merck & Co., Inc. is also one of the leading player in infectious disease treatment market. The company’s stronghold is largely attributed to its innovative and sustainable products. On May 30, 2017, Merck received FDA approval for ISENTRESS® HD used for the treatment of HIV infection in adults, and pediatric patients. On September 06, 2017, Merck & Co., Inc. teamed up with Rigontec to expand its Immuno-Oncology segment.
AbbVie Inc. is another renowned market player in infectious disease treatment market. On August 3, 2017, AbbVie received approval for its Hepatitis C treatment drug, named as Mavyret (glecaprevir and pibrentasvir).
Novartis AG (Switzerland), Gilead (U.S.), Janssen Pharmaceutical, Inc. (Belgium), F. Hoffmann-La Roche Ltd. (Germany), AbbVie Inc. (U.S.), GlaxoSmithKline plc (U.K), BioCryst Pharmaceuticals (U.S.), Merck & Co., Inc. (U.S.), and Boehringer Ingelheim GbH (Germany) are some of the prominent players at the forefront of competition in the infectious disease treatment market and are profiled in MRFR Analysis.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/1626 .
Infectious Disease Treatment Market Regional Analysis:
The Americas dominate the global infectious disease treatments market. A well-developed healthcare sector and huge patient population for infectious diseases followed by increasing healthcare expenditure and changing lifestyle drive the market growth in the Americas. Moreover, the presence of global players like Merck & Co., Inc., Pfizer Inc., and others within the region fuels the market growth during the forecast period.
Europe is the second largest infectious disease treatments market. High healthcare expenditures, government support for research & development, and huge patient population drives the European market. Moreover, the presence of the developed economies within the region like Germany, the U.K, and France fuels the market growth during the forecast period.
Asia Pacific is the fastest growing region in the global market due to the presence of a huge patient population and continuously developing economies like India and China which have a growing healthcare industry. Additionally, favorable government policies like reduced excise and customs duty followed by the exemptions in service tax in India boosts the regional market growth.
On the other hand, the Middle East & Africa holds the least share in the global infectious disease treatments market due to the presence of poor economies in the African region. Moreover, the low per capita income and stringent government policies restrain the market growth within the African region. A majority of the market in the Middle East & Africa is held by the Middle East due to huge healthcare expenditures and presence of developed economies like Kuwait, Saudi Arabia, Dubai, and Qatar.
Global Infectious Disease Treatments Market Segmentation:
The Global Infectious Disease Treatments Market is segmented on the basis of type, treatment, and end users.
On the basis of the type, the market is segmented into viral diseases, bacterial diseases, and others. The viral diseases segment is sub-segmented into acquired immunodeficiency syndrome (AIDS), hepatitis B, hepatitis C, and others. The bacterial diseases segment is sub-segmented into tuberculosis (TB), bacterial meningitis, and others.
On the basis of the treatment, the market is segmented into antibacterial drugs, antifungal drugs, antiviral drugs, anti-parasitic drugs, and others. The antibacterial drugs segment is sub-segmented into beta-lactams, quinolones, sulfonamides, tetracyclines, and others. The antifungal drugs segment is sub-segmented into azoles, pyrimidines, echinodians, polyenes, and others.
On the basis of application, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
On the basis of the end users, the market is segmented into hospitals & clinics, research organization, retail pharmacies, and others.
Inquire more @ https://www.marketresearchfuture.com/enquiry/1626 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312